Legend Biotech Corp
About Legend Biotech Corp
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $6.1B
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $6.1B
- Shares outstanding
- 173.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 5, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 21% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Legend Biotech Corp.
Write a review
News about Legend Biotech Corp
News & sentiment via Polygon.io
